https://ipharmag.com/article/novo-nordisk-anthropic-ai-drug-development iPharmag en 2026-09-17T00:00:04+00:00 Novo Nordisk Enlists Anthropic’s AI to ‘Supercharge’ Its Drug Development https://ipharmag.com/article/novartis-sironax-blood-brain-barrier-delivery-125m iPharmag en 2026-09-17T00:00:04+00:00 Novartis Pays $125M for a Way to Sneak Big Drugs Past the Brain’s Border Wall https://ipharmag.com/article/microprotein-atlas-microglia-alzheimers-salk iPharmag en 2026-09-17T00:00:04+00:00 Scientists Map a Hidden Layer of Brain Proteins — and Find New Clues to Alzheimer’s https://ipharmag.com/article/fda-kybella-deoxycholic-acid-unapproved-use-warning iPharmag en 2026-09-17T00:00:04+00:00 FDA Warns of Serious Injuries From ‘Off-Label’ Use of the Double-Chin Fat Dissolver https://ipharmag.com/article/colonoscopy-surveillance-interval-low-risk-polyps iPharmag en 2026-09-17T00:00:04+00:00 After Low-Risk Polyps, You May Not Need Another Colonoscopy So Soon https://ipharmag.com/article/vera-trutakna-atacicept-iga-nephropathy-phase3 iPharmag en 2026-09-16T00:39:24+00:00 Vera’s Kidney Drug Nearly Halted Disease Progression in a Two-Year Trial https://ipharmag.com/article/knee-osteoarthritis-best-nondrug-treatments-meta-analysis iPharmag en 2026-09-16T00:39:24+00:00 What Actually Helps Knee Arthritis? A 10,000-Patient Analysis Ranks the Options https://ipharmag.com/article/gsk-chimagen-750m-tce-multiple-myeloma-deal iPharmag en 2026-09-16T00:39:24+00:00 GSK Doubles Down on Cancer With a $750M Bet on a Triple-Targeting Immune Drug https://ipharmag.com/article/curium-bexlutry-first-generic-radioligand-fda iPharmag en 2026-09-16T00:39:24+00:00 FDA Clears the First-Ever Generic of a Radioactive Cancer Drug https://ipharmag.com/article/brain-aging-shift-50-75-hippocampus-study iPharmag en 2026-09-16T00:39:24+00:00 The Brain Goes Through a Major Remodeling Between Ages 50 and 75, Study Finds